Combining talimogene laherparepvec (T-VEC) with pembrolizumab did not lead to a survival benefit for patients with advanced melanoma.
Archive | Clinical Trials
Oncolytic Therapy Adds No Survival Benefit to PD-1 Treated Advanced Melanoma
Posted in Melanoma News, Health Professionals, Clinical Trials
Oncolytic Therapy Adds No Survival Benefit to PD-1 Treated Advanced Melanoma
Combining talimogene laherparepvec (T-VEC) with pembrolizumab did not lead to a survival benefit for patients with advanced melanoma.
Posted in Melanoma News, Health Professionals, Clinical Trials
Relatlimab/Nivolumab Improves TFI and PFS2 in Frontline Advanced Melanoma
The addition of relatlimab to nivolumab (Opdivo) prolonged benefit beyond initial treatment and first progression and reduced the risk of progression…
Posted in Melanoma News, Health Professionals, Clinical Trials
Adjuvant Pembrolizumab Induces RFS Benefit in Resected High-Risk Stage II Melanoma
Adjuvant pembrolizumab (Keytruda) led to a significant reduction in the risk of disease recurrence or death compared with placebo in patients with resected, high-risk stage II melanoma…
Posted in Melanoma News, Health Professionals, Clinical Trials
